MultiCell Announces Online Availability of Video Presentation Outlining Company's Pipeline of Novel Drug Candidates; Company President Discusses Therapeutic Compounds to Treat Multiple Sclerosis and Other Serious Autoimmune Diseases.SAN DIEGO San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. -- MultiCell Technologies, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :MCET MCET Massachusetts Corporation for Educational Telecommunications MCET Maryland Center for Environmental Training MCET Micro-Computer Electronics Technology MCET Michigan Consumer Evaluation Team, Inc ), a developer of therapeutics for the treatment of degenerative neurological diseases, metabolic and endocrinological disorders, and infectious diseases, announced the availability of a new webcast highlighting MultiCell's proprietary medical technologies and market advantages. The streaming video shows a presentation by MultiCell President Dr. Stephen Chang at a recent meeting of the Southern California Investment Association (SCIA SCIA Smart Card Industry Association SCIA South Central Industrial Association SCIA Semiconductor Industry Association SCIA Simultaneous Converging Instrument Approaches SCIA St. ) Conference. Dr. Chang provides an overview of MultiCell's proprietary drug candidates and clinical development goals. MultiCell's portfolio of drug candidates includes compounds designed to treat serious autoimmune diseases Autoimmune diseases A group of diseases, like rheumatoid arthritis and systemic lupus erythematosus, in which immune cells turn on the body, attacking various tissues and organs. Mentioned in: Complement Deficiencies, Premature Menopause , including multiple sclerosis and Type-1 diabetes. The Company's lead drug candidates include MCT-125, which has been shown to be effective in Phase II clinical trials for the treatment of fatigue in multiple sclerosis patients. MultiCell expects to commence a Phase IIb/III trial later this year for MCT-125. MultiCell's autoimmune disease autoimmune disease, any of a number of abnormal conditions caused when the body produces antibodies to its own substances. In rheumatoid arthritis, a group of antibody molecules called collectively RF, or rheumatoid factor, is complexed to the individual's own gamma drug candidates include therapeutic compounds designed to treat the primary symptoms of multiple sclerosis, type-1 diabetes, macular degeneration macular degeneration, eye disorder causing loss of central vision. The affected area, the macula, lies at the back of the retina and is the part that produces the sharpest vision. and influenza A influenza A n. Influenza caused by infection with a strain of influenza virus type A. influenza A Infectious disease An avian virus, especially of ducks–which in China live near the pig reservoir and 'vector'; infection. The webcast is approximately 20 minutes in length. To view the presentation, please visit www.sciaonline.org, and click on the menu items in the following order: "Watch Recent Presenters Here," "Public Companies," and "MultiCell Technologies, Inc." About MultiCell Technologies, Inc. MultiCell Technologies, Inc. is a biopharmaceutical company committed to the development of breakthrough therapeutics based on a portfolio of therapeutic candidates and patented drug development technology platforms. The Company's drug development programs are focused on modulation of the immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. . The Company's lead drug candidates include drugs to treat fatigue resulting from multiple sclerosis, relapse-remitting multiple sclerosis, and type-1 diabetes. Other therapeutic candidates in the MultiCell development pipeline include new antiviral antiviral /an·ti·vi·ral/ (-vi´ral) destroying viruses or suppressing their replication, or an agent that so acts. an·ti·vi·ral adj. treatments to address worldwide influenza threats as well as treatments for other infectious diseases. The Company also holds unique cell-based technology for use in drug discovery screening applications and is a leading producer of the cell lines needed by the biotechnology industry to develop new drugs and therapeutics. For more information on MultiCell, please visit http://www.multicelltech.com. Forward-Looking Statements Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 (the "Act"). These statements are often, but not always, made through the use of words or phrases such as "believe," "will," "expect," "anticipate," "estimate," "intend," "plan," "forecast," "could," and "would." Examples of such forward-looking statements include statements regarding the timing, design, scope, and anticipated results of our clinical development of MCT-125, and worldwide sales relating to MCT-125. MultiCell bases these forward-looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize MCT-125 as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations. For additional information about risks and uncertainties MultiCell faces, see documents MultiCell files with the SEC, including MultiCell's report on Form 10-KSB for the fiscal year ended November 30, 2005, and all our quarterly and other periodic SEC filings. MultiCell claims the protection of the safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. for forward-looking statements under the Act and each assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion